Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Cathy Eng, Takayuki Yoshino et al.|The Lancet|2023Cited by 319
Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074Joon H. Uhm, Kurt A. Jaeckle, Karla V. Ballman et al.|International Journal of Radiation Oncology*Biology*Physics|2010Cited by 186